<DOC>
	<DOCNO>NCT00870688</DOCNO>
	<brief_summary>Valproate first line therapy primary generalized seizure . The applied drug contains sodium valproate sustain release minitablets . As multiple unit dosage form easily swallow take independent meal . A simple dosage scheme like valproate sustain release minitablets daily even improve compliance likely seizure situation patient . The data non interventional trial directly extract physician 's electronic patient database . The observational period 7 week compare retrospective period 7 week start study .</brief_summary>
	<brief_title>Valproate Sustained Release Minitablets ( Orfiril ( R ) Long ) Once Daily Evening</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>age 12 year epilepsy patient indication initiation / conversion valproate sustain release minitablets daily contraindication valproate use indication conversion valproate sustain release minitablets daily</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>valproate</keyword>
	<keyword>epilepsy</keyword>
	<keyword>compliance</keyword>
	<keyword>sustain release minitablet</keyword>
	<keyword>Orfiril long</keyword>
</DOC>